The two molecular biomarkers of significant interest that have translated into clinical practice are Isocitrate Dehydrogenase (IDH) and MGMT (O (2)-methylguanine-DNA methyltransferase), both of which are responsible for epigenetic alterations in glioblastomas. This evidence concerns the gene IDH1 and glioblastoma.